Immuneel Launches Qartemi, a CAR T-cell Therapy for Non-Hodgkin's Lymphoma in India
• Immuneel Therapeutics has launched Qartemi, India's first CAR T-cell therapy for treating adult B-cell Non-Hodgkin Lymphoma (B-NHL).
• Qartemi is a personalized therapy that modifies a patient’s T-cells to target and eliminate cancer cells, offering hope for lasting remission.
• Clinical trials in India and Spain demonstrated that Qartemi's safety and efficacy are similar to US FDA-approved CAR T-cell therapies.
• Priced at approximately ₹35 to ₹50 lakh, Qartemi is significantly more affordable than similar treatments in the US.
Gene Therapy Trial for Hemophilia Shows Success, Announced by Indian Biotechnology Research and Innovation Council
• A successful gene therapy trial for hemophilia, supported by the Department of Biotechnology, was announced at the Biotechnology Research and Innovation Council (BRIC) meeting.
• The trial, conducted at Christian Medical College, Vellore, has been reported in the prestigious New England Journal of Medicine.
• BRIC is playing a significant role in unifying governance across 14 biotechnology institutions to foster research, innovation, and capacity building in India.
• The i3c BRIC-RCB-PhD Programme was launched, enrolling 58 students to promote interdisciplinary research and hands-on training in biotechnology.
Indian Scientists Report Success with Novel Gene Therapy for Severe Hemophilia A
• A novel gene therapy developed in India has shown promising results in treating severe Hemophilia A, with a zero bleeding rate observed in treated patients.
• The gene therapy uses a lentiviral vector to introduce a corrected gene into stem cells, enabling the body to produce Factor VIII autonomously.
• This one-time treatment offers a potential lifelong solution, reducing the need for frequent and expensive clotting factor infusions.
• The initial trial, involving five patients, suggests this therapy could be a more affordable and accessible option for Hemophilia A patients in resource-constrained settings.
© Copyright 2025. All Rights Reserved by MedPath